Literature DB >> 7859808

Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.

R E Port1, H P Schlemmer, P Bachert.   

Abstract

NMR spectroscopy in vivo when applied to studying drugs and their metabolites usually measures relative concentration in a tissue over time. Only ratios of clearance and volume parameters can be estimated from these data. Low drug dosages (relative to the sensitivity of in vivo NMR) or rapid drug elimination create the additional problem of data sparsity where a pharmacokinetic model cannot be fitted individually. We have investigated whether relative and absolute pharmacokinetic parameters can be estimated from such data by applying a population model. The data analysed were relative concentrations of 5-fluorouracil (FU) and of the sum of its catabolites alpha-fluoro-beta-ureido-propanoic acid (FUPA) and alpha-fluoro-beta-alanine (FBAL) in the liver, as monitored in 16 cancer patients by [19F]-NMR spectroscopy during and after a 10-min intravenous infusion of 650 mg FU.m-2. The "structural" part of the population model was a non-linear, two-compartment model featuring one FU compartment with volume VFU, a saturable clearance of FU by conversion into the catabolites where CL = vmax/(kM+CFU), a catabolite compartment with volume Vcat, and a concentration-independent clearance of the catabolites, CLcat. The parameters actually fitted were: gamma, vmax, kM.VFU, Vcat/VFU, and CLcat/Vcat where gamma is a proportionality factor relating the NMR signal intensity of FU to the amount of FU in the body and, therefore, has no purely pharmacokinetic interpretation. All parameters were checked for random interindividual variation: gamma and vmax were also tested for inter-occasion variation. The program system NONMEM was used for model fitting.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7859808     DOI: 10.1007/bf00194971

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.

Authors:  C A Presant; W Wolf; M J Albright; K L Servis; R Ring; D Atkinson; R L Ong; C Wiseman; M King; D Blayney
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

2.  Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1960-02       Impact factor: 5.157

3.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

4.  The importance of modeling interoccasion variability in population pharmacokinetic analyses.

Authors:  M O Karlsson; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

Review 5.  Population pharmacokinetics. Theory and clinical application.

Authors:  B Whiting; A W Kelman; J Grevel
Journal:  Clin Pharmacokinet       Date:  1986 Sep-Oct       Impact factor: 6.447

6.  In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using 19F nuclear magnetic resonance spectroscopy.

Authors:  A el-Tahtawy; W Wolf
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

7.  Nonlinear pharmacokinetics for the elimination of 5-fluorouracil after intravenous administration in cancer patients.

Authors:  B J McDermott; H W van den Berg; R F Murphy
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

8.  Kinetic modeling of in vivo--nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors.

Authors:  R E Port; P Bachert; W Semmler
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

9.  Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance.

Authors:  R E Port; B Daniel; R W Ding; R Herrmann
Journal:  Oncology       Date:  1991       Impact factor: 2.935

10.  Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.

Authors:  W E Hull; R E Port; R Herrmann; B Britsch; W Kunz
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

View more
  1 in total

Review 1.  Noninvasive methods to study drug distribution.

Authors:  Ruediger E Port; Walter Wolf
Journal:  Invest New Drugs       Date:  2003-05       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.